United Therapeutics Corporation P/E Ratio 2008–2025
United Therapeutics Corporation reported 17.49 of price-to-earnings ratio for fiscal 2025. That was 22.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +33.0%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 17.49 | +22.1% |
| FY 2024 | 14.32 | +29.0% |
| FY 2023 | 11.10 | -40.1% |
| FY 2022 | 18.54 | -13.7% |
| FY 2021 | 21.48 | +63.3% |
| FY 2020 | 13.15 | — |
| FY 2019 | — | — |
| FY 2018 | 8.13 | -48.8% |
| FY 2017 | 15.89 | +69.0% |
| FY 2016 | 9.41 | -23.6% |
| FY 2015 | 12.31 | -40.3% |
| FY 2014 | 20.62 | -40.2% |
| FY 2013 | 34.48 | +268.5% |
| FY 2012 | 9.36 | -27.3% |
| FY 2011 | 12.87 | -63.8% |
| FY 2010 | 35.52 | -76.4% |
| FY 2009 | 150.43 | — |
| FY 2008 | — | — |
Source: United Therapeutics Corporation SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open UTHR 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
United Therapeutics Corporation reported 17.49 of price-to-earnings ratio for fiscal 2025. That was 22.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +33.0%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for United Therapeutics Corporation
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeUnited Therapeutics Corporation — frequently asked questions
What is United Therapeutics Corporation's price-to-earnings ratio?
United Therapeutics Corporation (UTHR) reported price-to-earnings ratio of 17.49 for fiscal year 2025, per its SEC filings.
How has United Therapeutics Corporation's price-to-earnings ratio changed over time?
Between fiscal 2008 and 2025, UTHR's price-to-earnings ratio declined at roughly 11.9% per year (compound annual rate), from 150.43 to 17.49.
Where does this data come from?
Figures are computed from United Therapeutics Corporation's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More UTHR financial history
Full UTHR fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →